We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

316 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 86 funds opening new positions, 114 increasing their positions, 62 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 34

84% more repeat investments, than reductions

Existing positions increased: 114 | Existing positions reduced: 62

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

18% more funds holding

Funds holding: 267 → 316 (+49)

18% more capital invested

Capital invested by funds: $1.74B → $2.06B (+$317M)

1% less call options, than puts

Call options by funds: $30.7M | Put options by funds: $30.9M

14.8% less ownership

Funds ownership: 94.22% → 79.42% (-15%)

Holders
316
Holders Change
+49
Holders Change %
+18.35%
% of All Funds
4.16%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
86
Increased
114
Reduced
62
Closed
34
Calls
$30.7M
Puts
$30.9M
Net Calls
-$211K
Net Calls Change
+$8.19M

Top Buyers

1
SoftBank Group
SoftBank Group
Japan
+$98.6M
2
NHAS
Novo Holdings A/S
Denmark
+$68M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$65.5M
4
BlackRock
BlackRock
New York
+$18.1M
5
Citadel Advisors
Citadel Advisors
Florida
+$16.8M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$51.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.68M
3
Voloridge Investment Management
Voloridge Investment Management
Florida
-$6.42M
4
NAMA
Nikko Asset Management Americas
New York
-$5.29M
5
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$5.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
51
Two Sigma Advisers
New York
$3.05M -$257K -38,155 -8%
Ensign Peak Advisors
52
Ensign Peak Advisors
Utah
$2.77M +$8.74K +1,300 +0.3%
BG
53
Bellevue Group
Switzerland
$2.55M -$101K -15,075 -4%
LPL Financial
54
LPL Financial
California
$2.49M +$49.4K +7,347 +2%
Jane Street
55
Jane Street
New York
$2.39M +$772K +114,822 +48%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$2.26M +$158K +23,564 +8%
Rockefeller Capital Management
57
Rockefeller Capital Management
New York
$1.91M +$1.45M +215,283 +323%
Group One Trading
58
Group One Trading
Illinois
$1.9M +$615K +91,529 +48%
Simplex Trading
59
Simplex Trading
Illinois
$1.78M -$143K -21,341 -7%
Legal & General Group
60
Legal & General Group
United Kingdom
$1.71M +$457K +67,953 +37%
CI
61
Carroll Investors
South Carolina
$1.67M +$566K +84,245 +52%
AllianceBernstein
62
AllianceBernstein
Tennessee
$1.64M +$174K +25,920 +12%
Osaic Holdings
63
Osaic Holdings
Arizona
$1.64M -$264K -39,277 -14%
Envestnet Asset Management
64
Envestnet Asset Management
Illinois
$1.57M +$78.3K +11,646 +5%
California State Teachers Retirement System (CalSTRS)
65
California State Teachers Retirement System (CalSTRS)
California
$1.57M +$366K +54,449 +31%
Deutsche Bank
66
Deutsche Bank
Germany
$1.47M +$511K +75,994 +54%
AO
67
Allen Operations
New York
$1.47M – – –
IEFM
68
IQ EQ Fund Management
Ireland
$1.36M +$794K +118,118 +143%
Russell Investments Group
69
Russell Investments Group
United Kingdom
$1.33M -$279K -41,446 -17%
TRSOTSOK
70
Teachers Retirement System of the State of Kentucky
Kentucky
$1.27M – – –
Capital Fund Management (CFM)
71
Capital Fund Management (CFM)
France
$1.24M +$1.24M +183,796 New
Invesco
72
Invesco
Georgia
$1.21M +$424K +63,068 +55%
State of Wisconsin Investment Board
73
State of Wisconsin Investment Board
Wisconsin
$1.15M +$527K +78,326 +85%
CC
74
Casdin Capital
New York
$1.12M +$1.11M +165,323 New
Mirae Asset Global ETFs Holdings
75
Mirae Asset Global ETFs Holdings
Hong Kong
$1.12M +$53.4K +7,939 +5%
1 2
3
4 5

RXRX Hedge Fund Activity: Q4 2024 in Review

316 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2024, worth a combined $2.06B — up 18% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 86 funds opened new RXRX positions and 34 closed out — a net gain of 52 holders — while 114 added to existing stakes and 62 trimmed.

The largest buyer was SoftBank Group, opening a new position worth an estimated $98.6M. The largest seller was RA Capital Management, cutting an estimated $51.5M.

  • 316 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2024, up from 267 in Q3 2024.
  • Funds reported $2.06B of Recursion Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
  • 86 funds opened new Recursion Pharmaceuticals positions in Q4 2024 and 34 closed out, a net change of +52 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2024 was SoftBank Group, an estimated $98.6M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2024 was RA Capital Management, an estimated $51.5M sold.

Based on aggregated 13F filings for Q4 2024.